Quick Look
An investment strategy suggests selling Cigna (CI) July $280 cash-secured puts for approximately $6 to generate income, offering a 2% return in six weeks or an effective purchase price of $274 if assigned, turning the stock into an income generator.
AI-generated summary
Why It Matters
The current market is characterized by high volatility in semiconductor stocks driven by AI headlines. The author seeks a stable, cash-generating business as a counterpoint.
With semis whipping around on every AI headline and index volatility spiking, I'm looking for a counterpoint, a stable, cash-generating business where I can sell volatility instead of buying drama.
Cigna (CI) fits the bill — and I'd rather write my way into the stock than chase it.
Cigna isn't a growth story. Revenue growth is steady if modest compared to the eye-watering numbers coming out of the semis. The company beat in the first quarter, reporting adjusted EPS of $7.79, and raised full-year guidance to at least $30.35 per share, extending a multi-year pattern of adjusted EPS growth. That marked the 5th consecutive (albeit modest) quarterly EPS beat. The stock is also supported by a substantial buyback program; ~ $2.5 billion remains on the $6 billion repurchase program announced early last year.
With the stock just over $290, you're paying roughly 9.5x forward earnings. Much less than half the turn one would pay for the S&P at current levels, with roughly double the dividend yield at 2.2%.
If the dividend is one of the reasons to buy the stock, one would have to wait until the first week of September to get the next one (CI goes ex-div on 9/4). So, to accelerate some potential income, rather than buying shares outright at $290, I'd sell the July $280 cash-secured put, which has recently traded in the neighborhood of $6.
Sell CI July put for $6
Max gain: $60
Max loss: $276
Skill level: Intermediate
Two things can happen, and either is acceptable. If CI stays above $280 through expiration, we keep the premium — roughly 2% on the cash securing the trade in about six weeks, an annualized yield in the mid-teens for agreeing to buy a 9.5x-earnings business at a discount.
If CI dips below $280 and we're assigned, our effective basis is around $274 a 5% discount to the current price and comfortably above the lower half of the 52-week range. From there, the second phase of the strategy kicks in: collect the dividend and systematically sell covered calls against the position, turning a stable managed-care franchise into a persistent income generator.
Like any trade, this isn't entirely riskless. Managed care carries headline risk, medical cost trends, and other risks. But that's precisely the point. We're assigned at a price we've already decided is reasonable to own.
And of course, selling the put will tie up a lot of margin in your account, but the capital commitment is the same as simply buying the stock.
When volatility keeps showing up uninvited, getting paid to set your own entry on a low volatility play can serve as a nice counterbalance to slow the swings in our portfolios.
What to Watch
AI outlook — possibilities, not facts
Cigna (CI) stock stays above $280 through July expiration.
Likely · Within weeks
Cigna (CI) stock dips below $280 through July expiration, leading to assignment.
Possible · Within weeks
The author collects the dividend and sells covered calls against the Cigna position if assigned.
Very likely · Within months
Open Questions
- What are the specific medical cost trends affecting managed care?
- What is the exact amount of margin required for the cash-secured put?
- What is the historical performance of Cigna's covered call strategy?
- What are the specific risks associated with Cigna's managed care business beyond headline risk?
